The inhibitory effects of the second messenger cAMP on T-cell proliferation and effector functions are well recognized (1) . However, little is known about the mechanisms by which the inhibitory effects occur. Recently, a novel cAMP-inducible transcriptional repressor protein has been described (2, 3) . This transrepressor, ICER, is expressed in neuroendocrine tissues such as the pineal, pituitary (2, 3) , and thyroid (4) glands under rhythmic, circadian control. ICER binds to cAMP response elements (CREs) that diverge considerably from the canonical CRE motif, TGACGTCA, and thereby inhibits CRE-binding transactivator proteins. These CREs include the cAMP autoregulatory response elements located in the promoter of the ICER gene. The expression of the ICER gene is stimulated by cAMP-activated transcription factors and is then repressed by negative autoregulatory feedback, thereby establishing a circadian control of ICER gene expression.
Because of the known circadian fluctuations in the proliferation and activities of lymphocytes (5, 6), we sought to determine whether high levels of intracellular cAMP in developing T lymphocytes could induce the expression of ICER and so implicate a potential role for ICER in the observed inhibitory effects of cAMP on mature T cells (1 respectively. RT-PCR cloning and sequencing were performed by using standard procedures (10) . RNase Protection Analysis. RNA extraction was performed as described (10) . RNA probe 1 is generated from pCREMhRIBO3 by BamHI (Fig. 3 A and  B) . Notably, no significant forskolin-mediated induction of ICER mRNA was detected in either cortical thymocytes or unfractionated (total) human thymocytes (Fig. 3B) . These findings correlate with the differences in cAMP levels observed after treating medullary and cortical thymocytes with forskolin ( Fig. IF) and confirm that ICER induction can be detected only in a subset of mature medullary thymocytes.
Of importance is that ICER is transcribed and translated exclusively from an internal promoter (P2) whose activity is stimulated by cAMP-responsive autoregulatory enhancers (3) (Fig. 2A) . To confirm that ICER is the only CREM isoform induced in thymocytes and that the constitutive P1 promoter is not used, a human CREM-y probe (probe 1) that contains exons from the 5' portion of the CREM gene upstream of the ICER-specific P2 promoter was used in the RNase protection assays (Fig. 3 A and C) . The length of protected ICER IIy fragment by the CREMy probe corresponded exactly to that observed with the ICER II RNA probe, indicating the absence of 5' sequences (P1 promoter induced) upstream of the P2 promoter in forskolin-induced CREM transcripts (Fig. 3C ). These results demonstrate that ICER IIy is the prevalent CREM isoform in the forskolin-treated Jurkat leukemic T-cell line ( Fig. 3 B and C 2), MOLT3 (lanes 3 and 4) , MOLT4 (lanes 5 and 6), HUT78 (lanes 7 and 8), and CEM (lanes 9 and 10). ICER induction was only faintly detectable under these conditions in the B-cell lines X-50-7 (11) (lanes 11 and 12), and AKATA (12) (lanes 13  and 14) . T forskolin reveals intense staining in nuclei with ICER-specific antiserum, but no detectable staining with pre-immune serum. Jurkat T cells were treated with forskolin (0.1 mM) and attached to slides after 24 h. Immunocytochemistry was performed with ICER specific antiserum raised in guinea pigs against a synthetic ICER-specific peptide (Ala-Val-Thr-Gly-Asp-Glu-Thr-Gly-Gly-Cys) (see Fig. 2A (Fig. 3C) . However, the protein synthesis inhibitor cycloheximide markedly potentiated the forskolin-induced elevation of ICER mRNA (FSK+CHX) (Fig. 3C) (Fig. 3E, (Fig. 3E, lanes 2 and 3) . The Fig. 1 E and G) (Fig. 5A) . Thus, ICER can be induced by, and substituted for, PGE2 in the transcriptional downregu- (20) or with the HTLV-I LTR-CAT (CR-CAT) reporter (B and C) (21) . To activate the calcineurin-dependent signal pathway, Jurkat cells were treated with PMA (10 ng/ml) and ionomycin (1 jig/ml) 16 
